RxDoctor Payments Data

Molly Glauner, APRN

Psychiatric/Mental Health · Topeka, KSNPI 1154054427

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 45 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$242
  • Alkermes, Inc.$191
  • AbbVie$114
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$112
  • Neurocrine Biosciences, Inc.$79
  • Novo Nordisk$71
  • plus $235 from 8 others

What the payments were for

  • Food & beverage$1,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044 in reported general payments places this provider in the 65th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$2,368
Medicare patients
31
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate68$231,148
Abilify MaintenaAripiprazole26$74,984
Austedo XrDeutetrabenazine11$63,516
VraylarCariprazine Hcl15$17,816
Lurasidone Hcl21$8,661
Clozapine61$5,557
Quetiapine Fumarate ErQuetiapine Fumarate12$3,441
Aripiprazole38$2,764
Quetiapine Fumarate55$1,128
Duloxetine Hcl92$1,109
Atomoxetine Hcl17$947
Oxcarbazepine20$872
Prazosin Hcl16$856
Olanzapine59$799
Clonazepam108$763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$242$231,14868 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$53$74,98426 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$61$63,51611 claims
AbbVieVraylar$114$17,81615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →